WallStreetZenWallStreetZen

NASDAQ: PBLS
Parabilis Medicines Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PBLS

Based on 3 analysts offering 12 month price targets for Parabilis Medicines Inc

Min Forecast
$40.00+39.37%
Avg Forecast
$41.67+45.18%
Max Forecast
$45.00+56.79%

Should I buy or sell PBLS stock?

Based on 3 analysts offering ratings for Parabilis Medicines Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PBLS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PBLS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their PBLS stock forecasts and price targets.

PBLS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-22
lockedlocked$00.00+00.00%2026-07-06
lockedlocked$00.00+00.00%2026-07-06
lockedlocked$00.00+00.00%2026-07-06

1 of 1

Forecast return on equity

Is PBLS forecast to generate an efficient return?

Company
-34.7%
Industry
-16.81%
Market
154.98%
PBLS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PBLS forecast to generate an efficient return on assets?

Company
-30.93%
Industry
-3.72%
PBLS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PBLS earnings per share forecast

What is PBLS's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$2.36
Avg 2 year Forecast
-$1.96
Avg 3 year Forecast
-$2.94

PBLS revenue forecast

What is PBLS's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$1.2M
Avg 2 year Forecast
$4.8M
Avg 3 year Forecast
$6.6M

PBLS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PBLS$28.70$41.67+45.18%Strong Buy
ACAD$20.76$30.92+48.95%Buy
XENE$37.54$67.50+79.81%Strong Buy
VKTX$26.86$96.50+259.27%Strong Buy
CELC$69.30$157.00+126.55%Strong Buy
View Top Biotech Stocks

Parabilis Medicines Stock Forecast FAQ

Is Parabilis Medicines Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: PBLS) stock is to Strong Buy PBLS stock.

Out of 3 analysts, 2 (66.67%) are recommending PBLS as a Strong Buy, 1 (33.33%) are recommending PBLS as a Buy, 0 (0%) are recommending PBLS as a Hold, 0 (0%) are recommending PBLS as a Sell, and 0 (0%) are recommending PBLS as a Strong Sell.

If you're new to stock investing, here's how to buy Parabilis Medicines stock.

What is PBLS's earnings growth forecast for 2026-2028?

(NASDAQ: PBLS) Parabilis Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.02%.

Parabilis Medicines's earnings in 2026 is N/A.On average, 7 Wall Street analysts forecast PBLS's earnings for 2026 to be -$291,699,040, with the lowest PBLS earnings forecast at -$374,083,357, and the highest PBLS earnings forecast at -$211,427,140. On average, 7 Wall Street analysts forecast PBLS's earnings for 2027 to be -$241,927,497, with the lowest PBLS earnings forecast at -$407,980,878, and the highest PBLS earnings forecast at -$154,354,783.

In 2028, PBLS is forecast to generate -$363,521,265 in earnings, with the lowest earnings forecast at -$460,037,786 and the highest earnings forecast at -$255,528,507.

What is PBLS's revenue growth forecast for 2026-2028?

(NASDAQ: PBLS) Parabilis Medicines's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 44.09%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.88%.

Parabilis Medicines's revenue in 2026 is N/A.On average, 6 Wall Street analysts forecast PBLS's revenue for 2026 to be $152,687,085, with the lowest PBLS revenue forecast at $0, and the highest PBLS revenue forecast at $402,100,696. On average, 6 Wall Street analysts forecast PBLS's revenue for 2027 to be $598,518,548, with the lowest PBLS revenue forecast at $0, and the highest PBLS revenue forecast at $1,297,099,020.

In 2028, PBLS is forecast to generate $819,025,381 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,686,228,726.

What is PBLS's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: PBLS) forecast ROA is -30.93%, which is lower than the forecast US Biotechnology industry average of -3.72%.

What is PBLS's Price Target?

According to 3 Wall Street analysts that have issued a 1 year PBLS price target, the average PBLS price target is $41.67, with the highest PBLS stock price forecast at $45.00 and the lowest PBLS stock price forecast at $40.00.

On average, Wall Street analysts predict that Parabilis Medicines's share price could reach $41.67 by Jul 6, 2027. The average Parabilis Medicines stock price prediction forecasts a potential upside of 45.18% from the current PBLS share price of $28.70.

What is PBLS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PBLS) Parabilis Medicines's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that PBLS's EPS will be -$2.36 for 2026, with the lowest EPS forecast at -$3.03, and the highest EPS forecast at -$1.71. On average, analysts forecast that PBLS's EPS will be -$1.96 for 2027, with the lowest EPS forecast at -$3.30, and the highest EPS forecast at -$1.25. In 2028, PBLS's EPS is forecast to hit -$2.94 (min: -$3.72, max: -$2.07).

What is PBLS's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: PBLS) forecast ROE is -34.7%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.